Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials
We conducted a systematic review and metaanalysis of randomized placebo-controlled trials in moderate-to-severe psoriasis treated with biological agents, with a follow-up of 10-14 weeks. Overall, 41 studies, with mean Jadad score of 4.4, and 15,586 patients were included. For the efficacy outcomes P...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz
2013-01-01
|
| Series: | Cadernos de Saúde Pública |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2013001300003&lng=en&tlng=en |
| _version_ | 1811298334731665408 |
|---|---|
| author | Cassyano Januário Correr Inajara Rotta Thaís de Souza Teles Rangel Ray Godoy Bruno Salgado Riveros Mariana Martins Garcia Patrícia Rodrigues Gonçalves Michel Fleith Otuki |
| author_facet | Cassyano Januário Correr Inajara Rotta Thaís de Souza Teles Rangel Ray Godoy Bruno Salgado Riveros Mariana Martins Garcia Patrícia Rodrigues Gonçalves Michel Fleith Otuki |
| author_sort | Cassyano Januário Correr |
| collection | DOAJ |
| description | We conducted a systematic review and metaanalysis of randomized placebo-controlled trials in moderate-to-severe psoriasis treated with biological agents, with a follow-up of 10-14 weeks. Overall, 41 studies, with mean Jadad score of 4.4, and 15,586 patients were included. For the efficacy outcomes PASI 50, 75 and 90 our findings are not conclusive to point what biological agent has the greatest response in short term follow-up. There were no statistical differences between placebo and biologics for the occurrence of infections and serious adverse events. Ustekinumab 45mg showed lower withdrawal due to adverse events compared with the placebo. Based on data available up to now, it is not possible to determine which biological agent is the best for PASI 50, 75 or 90 after 10-14 weeks of treatment. At the same follow-up, overall safety seems to be the same for all biological agents and Ustekinumab 45mg the most well tolerated drug. To better understand efficacy and safety, indirect meta-analysis comparing drug-to-drug is required since randomized placebo-controlled trials may not be feasible. |
| first_indexed | 2024-04-13T06:18:51Z |
| format | Article |
| id | doaj.art-3ce99ac20e6b40b5878a0c2e86d64126 |
| institution | Directory Open Access Journal |
| issn | 1678-4464 |
| language | English |
| last_indexed | 2024-04-13T06:18:51Z |
| publishDate | 2013-01-01 |
| publisher | Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz |
| record_format | Article |
| series | Cadernos de Saúde Pública |
| spelling | doaj.art-3ce99ac20e6b40b5878a0c2e86d641262022-12-22T02:58:44ZengEscola Nacional de Saúde Pública, Fundação Oswaldo CruzCadernos de Saúde Pública1678-44642013-01-0129suppl 1s17s3110.1590/0102-311X00157013S0102-311X2013001300003Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trialsCassyano Januário Correr0Inajara Rotta1Thaís de Souza Teles2Rangel Ray Godoy3Bruno Salgado Riveros4Mariana Martins Garcia5Patrícia Rodrigues Gonçalves6Michel Fleith Otuki7Universidade Federal do ParanáUniversidade Federal do ParanáUniversidade Federal do ParanáUniversidade Federal do ParanáUniversidade Federal do ParanáUniversidade Federal do ParanáUniversidade Federal do ParanáUniversidade Federal do ParanáWe conducted a systematic review and metaanalysis of randomized placebo-controlled trials in moderate-to-severe psoriasis treated with biological agents, with a follow-up of 10-14 weeks. Overall, 41 studies, with mean Jadad score of 4.4, and 15,586 patients were included. For the efficacy outcomes PASI 50, 75 and 90 our findings are not conclusive to point what biological agent has the greatest response in short term follow-up. There were no statistical differences between placebo and biologics for the occurrence of infections and serious adverse events. Ustekinumab 45mg showed lower withdrawal due to adverse events compared with the placebo. Based on data available up to now, it is not possible to determine which biological agent is the best for PASI 50, 75 or 90 after 10-14 weeks of treatment. At the same follow-up, overall safety seems to be the same for all biological agents and Ustekinumab 45mg the most well tolerated drug. To better understand efficacy and safety, indirect meta-analysis comparing drug-to-drug is required since randomized placebo-controlled trials may not be feasible.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2013001300003&lng=en&tlng=enPsoriasisAgentes BiológicosEficaciaSeguridadEvaluácion de Tecnologías de Salud |
| spellingShingle | Cassyano Januário Correr Inajara Rotta Thaís de Souza Teles Rangel Ray Godoy Bruno Salgado Riveros Mariana Martins Garcia Patrícia Rodrigues Gonçalves Michel Fleith Otuki Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials Cadernos de Saúde Pública Psoriasis Agentes Biológicos Eficacia Seguridad Evaluácion de Tecnologías de Salud |
| title | Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of biologics in the treatment of moderate to severe psoriasis a comprehensive meta analysis of randomized controlled trials |
| topic | Psoriasis Agentes Biológicos Eficacia Seguridad Evaluácion de Tecnologías de Salud |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2013001300003&lng=en&tlng=en |
| work_keys_str_mv | AT cassyanojanuariocorrer efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials AT inajararotta efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials AT thaisdesouzateles efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials AT rangelraygodoy efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials AT brunosalgadoriveros efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials AT marianamartinsgarcia efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials AT patriciarodriguesgoncalves efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials AT michelfleithotuki efficacyandsafetyofbiologicsinthetreatmentofmoderatetoseverepsoriasisacomprehensivemetaanalysisofrandomizedcontrolledtrials |